Ethyl 3-(4-hydroxyphenyl)pentanoate | 1356181-72-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Ethyl 3-(4-hydroxyphenyl)pentanoate
• 英文别名: ethyl 3-(4-hydroxyphenyl)pentanoate
• CAS: 1356181-72-0
• 化学式: C₁₃H₁₈O₃
• 分子量: 222.284
• InChiKey: HZICKANDXKPTFR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-[(4-甲氧基苯基)甲氧基]苯甲醛 在 哌啶 、 4-二甲氨基吡啶 、 水 、 溶剂黄146 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 生成 Ethyl 3-(4-hydroxyphenyl)pentanoate
  参考文献：
  名称：

  AMG 837: A potent, orally bioavailable GPR40 agonist

  摘要：

  The discovery that certain long chain fatty acids potentiate glucose stimulated insulin secretion through the previously orphan receptor GPR40 sparked interest in GPR40 agonists as potential antidiabetic agents. Optimization of a series of beta-substituted phenylpropanoic acids led to the identification of (S)-3-(44(4'-(trifluoromethyl)biphenyl-3-yl)methoxy)phenyl)hex-4-ynoic acid (AMG 837) as a potent GPR40 agonist with a superior pharmacokinetic profile and robust glucose-dependent stimulation of insulin secretion in rodents. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.10.118

文献信息

• [EN] GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT<br/>[FR] AGONISTE DU RÉCEPTEUR GPR40, PROCÉDÉS DE PRÉPARATION DE CELUI-CI, ET COMPOSITIONS PHARMACEUTIQUES CONTENANT CELUI-CI EN TANT QUE SUBSTANCE ACTIVE
  申请人：LG LIFE SCIENCES LTD

  公开号：WO2014073904A1

  公开（公告）日：2014-05-15

  The present invention relates to a novel compound having GPR40 receptor agonist activity that promotes insulin secretion and inhibits blood sugar rise after glucose loading, and is thereby useful for the treatment of diabetes and complications thereof, the preparation method thereof and pharmaceutical composition containing them as an active ingredient.

  本发明涉及一种具有GPR40受体激动剂活性的新化合物，可促进胰岛素分泌并抑制葡萄糖负荷后血糖升高，因此适用于糖尿病及其并发症的治疗，以及包含它们作为活性成分的制备方法和药物组合物。
• GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT
  申请人：LG LIFE SCIENCES LTD.

  公开号：US20150291584A1

  公开（公告）日：2015-10-15

  The present invention relates to a novel compound having GPR40 receptor agonist activity that promotes insulin secretion and inhibits blood sugar rise after glucose loading, and is thereby useful for the treatment of diabetes and complications thereof, the preparation method thereof and pharmaceutical composition containing them as an active ingredient.

  本发明涉及一种新型化合物，具有GPR40受体激动剂活性，促进胰岛素分泌并抑制葡萄糖负荷后血糖升高，因此可用于糖尿病及其并发症的治疗，其制备方法和含有其作为活性成分的药物组合物。
• GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT
  申请人：LG Life Sciences Ltd.

  公开号：EP2917180A1

  公开（公告）日：2015-09-16
• US9988379B2
  申请人：——

  公开号：US9988379B2

  公开（公告）日：2018-06-05
• AMG 837: A potent, orally bioavailable GPR40 agonist
  作者：Jonathan B. Houze、Liusheng Zhu、Ying Sun、Michelle Akerman、Wei Qiu、Alex J. Zhang、Rajiv Sharma、Michael Schmitt、Yingcai Wang、Jiwen Liu、Jinqian Liu、Julio C. Medina、Jeff D. Reagan、Jian Luo、George Tonn、Jane Zhang、Jenny Ying-Lin Lu、Michael Chen、Edwin Lopez、Kathy Nguyen、Li Yang、Liang Tang、Hui Tian、Steven J. Shuttleworth、Daniel C.-H. Lin

  DOI：10.1016/j.bmcl.2011.10.118

  日期：2012.1

  The discovery that certain long chain fatty acids potentiate glucose stimulated insulin secretion through the previously orphan receptor GPR40 sparked interest in GPR40 agonists as potential antidiabetic agents. Optimization of a series of beta-substituted phenylpropanoic acids led to the identification of (S)-3-(44(4'-(trifluoromethyl)biphenyl-3-yl)methoxy)phenyl)hex-4-ynoic acid (AMG 837) as a potent GPR40 agonist with a superior pharmacokinetic profile and robust glucose-dependent stimulation of insulin secretion in rodents. (C) 2011 Elsevier Ltd. All rights reserved.